Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Histamine H2 Antagonism as Adjuvant Therapy in Treatment Resistant Schizophrenia

NCT01946295 is registered in ClinicalTrials.gov with Jesper Ekelund as lead sponsor.

NCT NCT01946295
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01946295 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Histamine H2 Antagonism as Adjuvant Therapy in Treatment Resistant Schizophrenia
Lead sponsor
Jesper Ekelund
Phase
Phase 2/3
Overall status
Unknown status
Start date
March 31, 2014
Completion date
August 31, 2016
Enrollment
140 (estimated)
Sites
6

Conditions

As the registry lists them; a condition with its own page is linked.

schizophrenia